RT Journal Article
SR Electronic
T1 Vaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.28.22272975
DO 10.1101/2022.03.28.22272975
A1 Wang, Jing Jing
A1 Armour, Bridie
A1 Chataway, Tim
A1 Troelnikov, Alexander
A1 Colella, Alex
A1 Yacoub, Olivia
A1 Hockley, Simon
A1 Tan, Chee Wee
A1 Gordon, Tom Paul
YR 2022
UL http://medrxiv.org/content/early/2022/04/04/2022.03.28.22272975.abstract
AB Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare thromboembolic complication of adenoviral-vectored SARS-CoV2 vaccines, mediated by antibodies directed against platelet factor 4 (PF4). Given their causal role in VITT, identification of the molecular composition of anti-PF4 antibodies is crucial for developing better diagnostics and treatments. Here, we utilised a novel proteomic workflow to analyse the immunoglobulin variable (IgV) region composition of anti-PF4 antibodies at the level of the secreted proteome. Serum anti-PF4 IgG antibodies from five patients with VITT triggered by ChAdOx1 nCoV-19 vaccination were affinity purified by PF4-coupled magnetic beads and sequenced by mass spectrometry. We revealed a single IgG heavy (H)-chain species paired with a single lambda light (L)-chain species in all five unrelated patients. Remarkably, all L-chains were encoded by the identical IGLV3-21*02 gene subfamily with identical L-chain third complementarity determining region (LCDR3) lengths. Moreover, striking stereotypic features were also identified in heavy-chains anti-PF4 antibodies characterised by identical HCDR3 length and homologous sequences. In summary, we unravelled the molecular signature of highly stereotyped clonotypic anti-PF4 antibodies, indicating shared pathways of antibody production in VITT patients. These discoveries are critical to understand the molecular basis of this serious condition and develop novel therapies aimed at removing pathogenic clones.KEY POINTSAnti-PF4 antibodies in VITT comprise highly stereotyped clonotypeA single IGLV3-21*02 encoded light chain is found in unrelated patientsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementJ.J.W. is supported by Flinders University DVCR Fellowship and Flinders Health & Medical Research Institute COVID-19 Research Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Clinical Ethics Committee of the Flinders Medical Centre (Adelaide, South Australia) using de-identified diagnostic sera.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.